Q-omics provides the consensus-scored CFAP20DC profile across patient tissues and cancer cell-line models. CFAP20DC expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CFAP20DC is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, CFAP20DC RNA expression shows 18,622 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, BLCA, and THYM as cancer lineages where CFAP20DC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFAP20DC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFAP20DC survival associations across molecular data types. CFAP20DC RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFAP20DC RNA expression–survival associations across cancer types. High CFAP20DC expression shows unfavorable associations in KICH, UCEC, STAD and LIHC, but favorable associations in KIRP and SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CFAP20DC RNA expression.
This table summarizes CFAP20DC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CFAP20DC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFAP20DC shows higher tumor expression in BLCA, KIRC, KIRP, LUAD, COAD and LIHC. The BLCA box plot shows higher CFAP20DC RNA expression in tumor versus normal tissue (log2 FC = +1.834, t-test p < 0.001).
This table shows molecular features associated with CFAP20DC in patient tissues and cancer cell lines. In patient samples, CFAP20DC shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CFAP20DC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
